1,500 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Venturi Wealth Management LLC

Venturi Wealth Management LLC acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,500 shares of the biotechnology company’s stock, valued at approximately $131,000.

Other institutional investors have also made changes to their positions in the company. Quarry LP acquired a new stake in shares of Blueprint Medicines during the third quarter valued at about $32,000. R Squared Ltd acquired a new stake in shares of Blueprint Medicines during the fourth quarter valued at about $51,000. Covestor Ltd increased its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares during the last quarter. Asset Management One Co. Ltd. acquired a new stake in shares of Blueprint Medicines during the fourth quarter valued at about $88,000. Finally, Van ECK Associates Corp increased its position in shares of Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 363 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BPMC shares. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Piper Sandler lifted their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Wells Fargo & Company dropped their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Saturday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $123.83.

Insider Transactions at Blueprint Medicines

In other news, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now owns 14,967 shares of the company’s stock, valued at $1,395,822.42. This represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,851 shares of company stock worth $4,984,696. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Stock Down 2.2 %

Shares of Blueprint Medicines stock opened at $92.25 on Friday. Blueprint Medicines Co. has a 52-week low of $80.42 and a 52-week high of $121.90. The company has a 50 day moving average of $99.55 and a 200 day moving average of $94.40. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $5.90 billion, a P/E ratio of -85.42 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.